Related Experiment Videos

[Functional interaction between estrogen receptor and proto-oncogene products c-Jun and c-Fos]

V Doucas1, M Yaniv

  • 1UA 1149 du CNRS, Département des Biotechnologies, Institut Pasteur, Paris.

Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales
|January 1, 1991
PubMed

Insights

TPA treatment represses estrogen receptor activity and boosts AP1 binding in MCF-7 cells. This inhibition of estrogen-dependent growth is linked to the overexpression of cJun and cFos proteins.

Area of Science:

  • Molecular biology
  • Cell signaling
  • Cancer research

Context:

  • MCF-7 cells are a human breast cancer cell line commonly used in research.
  • Estrogen receptor (ER) signaling plays a crucial role in the growth of many breast cancers.
  • AP1 (activator protein 1) is a transcription factor involved in cell proliferation and differentiation.

Purpose:

  • To investigate the molecular mechanisms by which TPA (12-O-tetradecanoylphorbol-13-acetate) affects ER transcriptional activity and AP1 binding in MCF-7 cells.
  • To determine the role of cJun, cFos, and JunD in mediating the effects of TPA on ER activity and cell growth.

Summary:

  • TPA treatment of MCF-7 cells leads to decreased ER-dependent transcriptional activity and increased AP1 binding activity.
  • Overexpression of cJun or cFos, components of the AP1 transcription factor, represses ER transcriptional activity.
  • JunD overexpression did not result in ER repression, suggesting pathway specificity.
  • The findings suggest that TPA's inhibition of estrogen-dependent MCF-7 cell growth is mediated by the overexpression of cJun and cFos.

Impact:

  • Provides insights into the cross-talk between ER and AP1 signaling pathways in breast cancer cells.
  • Identifies potential therapeutic targets for managing estrogen-dependent breast cancers.
  • Contributes to understanding the complex regulatory mechanisms governing cell growth and gene expression.

Related Concept Videos